1Senzaki H, Masurtani S, Kobayashi J, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation, 2001,104 : 860-863.
2Takeshita S, Tokutomi T, Kawase H, et al. Elevated serum levels of matrix metalloproteinase-9(MMP-9) in Kawasaki disease. Clin Exp Immunol, 2001,125:340-344.
3Chua PK, Melish ME, Yu Q, et al. Elevated levels of metalloproteinase 9 and tissue inhibitor of metalloproteinases 1 during the acute phase of Kawasaki disease. Clin Diagn Lab Immunol,2003, 10:308-314.
4Tamarina NA, McMillan WD, Shively VP, et al. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery, 1997,122:264-271.
5Orbe J, Fernandez L, Rodriguez JA, et al. Different expression of MMPs/TIMP-1 in human atherosclerotic lesions. Relation to plaque features and vascular bed. Atherosclerosis, 2003, 170:269-276.
6Inoue T, Kato T, Takayanagi K, et al. Circulating matrix metalloproteinase-1 and -3 in patients with an acute coronary syndrome. Am J Cardiol, 2003, 92:1461-1464.
7Albisetti M, Chan AK, McCrindle BW, et al. Fibrinolytic response to venous occlusion is decreased in patients after Kawasaki disease.Blood Coagul Fibrinolysis, 2003, 14 : 181-186.
8Takeshita S, Nakatani K, Kawase H, et al. The role of bacteriallipopolysaccharide-bound neutrophils in the pathogenesis of Kawasaki disease. J Infect Dis, 1999,179:508-512.
9Gavin PJ, Crawford SE, Shulman ST, et al. Systemic arterial expression of matrix metaUoproteinases 2 and 9 in Kawasaki disease.Arterioscler Thromb Vasc Biol, 2003,23:576-581.
10Senzaki H, Masutani S, Kobayashi J, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation, 2001, 104:860-863.
